



# Notice of Results

October 16, 2020

RNS Number : 2682C

Renalytix AI PLC

16 October 2020

**Renalytix AI plc**  
("RenalytixAI" or the "Company")

**Notice of results**  
*Analyst and Investor presentations*

***RenalytixAI To Announce Financial Results for Full Year Ended June 30, 2020 and Provide Corporate Update***

**NEW YORK, October 16, 2020** - Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces that it will report its audited financial results for the full year ended June 30, 2020 on Tuesday, October 27 2020.

## **Analyst conference call**

The Company will hold an analyst conference call at 8:30 a.m. (EDT) / 12:30 p.m. (GMT) p.m. on Tuesday, October 27 2020. James McCullough, CEO and O. James Sterling, CFO will discuss the full year financial results and provide a corporate update.

## **Conference Call Details**

US/Canada Participant Toll-Free Dial-In Number: (833) 614-1551

US/Canada Participant International Dial-In Number: (914) 987-7290

United Kingdom Participant Dial-In Number: 080 0028 8438

United Kingdom, London Participant Dial-In Number: 020 3107 0289

Conference ID: 7673467

## **Webcast Registration link:**

<https://edge.media-server.com/mmc/p/6gfpm3i>

### **UK Retail Investor presentation**

RenalytixAI will be hosting a live online presentation open to all investors at 12.30 p.m. (EDT) / 4.30 p.m. (GMT) on Tuesday, October 27 2020. The Company is committed to providing an opportunity for all existing and potential investors to hear directly from management on the recent developments and additionally providing an update on the business, which will be provided by both James McCullough, CEO and O. James Sterling, CFO.

The presentation will be hosted through the digital platform Investor Meet Company. Investors can sign up to Investor Meet Company for free and add to meet RenalytixAI plc via the following link:

<https://www.investormeetcompany.com/renalytix-ai-plc/register-investor>

For those investors who have already registered and added to meet the Company, they will automatically be invited.

### ***For further information, please contact:***

#### **Renalytix AI plc**

James McCullough, CEO

[www.renalytixai.com](http://www.renalytixai.com)

**Via Walbrook PR**

#### **Stifel (Nominated Adviser, Joint Broker)**

Alex Price / Nicholas Moore

**Tel: 020 7710 7600**

#### **N+1 Singer (Joint Broker)**

Aubrey Powell / George Tzimas (Corporate Finance)

Tom Salvesen (Corporate Broking)

**Tel: 020 7496 3000**

#### **Walbrook PR Limited**

Paul McManus / Lianne Cawthorne

**Tel: 020 7933 8780** or [renalytix@walbrookpr.com](mailto:renalytix@walbrookpr.com)

Mob: 07980 541 893 / 07584 391 303

#### **US Investor Contact:**

Gilmartin Group

Carrie Mendivil / Kelly Gura

[investors@renalytixai.com](mailto:investors@renalytixai.com)

+ 1 (415)-937-5405

### **About Kidney Disease**

Kidney disease is now recognized as a public health epidemic affecting over 850 million people globally. The Centers for Disease Control and Prevention (CDC) estimates that 15% of US adults, or 37 million people, currently have chronic kidney disease (CKD). Further, the CDC reports that 9 out of 10 adults with CKD do not know they have it and 1 out of 2 people with very low kidney function who are not on dialysis do not know they have CKD\*. Kidney disease is referred to as a "silent killer" because it often has no symptoms and can go undetected until a very advanced stage. Each year kidney disease kills more people than breast and prostate cancer. Every day, 13 patients in the United States die while waiting for a kidney transplant.

\* <https://www.cdc.gov/kidneydisease/publications-resources/2019-national-facts.html>

### **About RenalytixAI**

RenalytixAI is a developer of artificial intelligence-enabled clinical *in vitro* diagnostic solutions for

kidney disease, one of the most common and costly chronic medical conditions globally. RenalytixAI's products are being designed to make significant improvements in kidney disease diagnosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery. For more information, visit [www.renalytixai.com](http://www.renalytixai.com).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NORFFAFUIESSELS